Log In
BCIQ
Print this Print this
 

epoetin alfa (subcutaneous Binocrit)

Also known as: Biosimilar erythropoietin

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
Description Subcutaneous biosimilar version of erythropoietin (EPO)
Molecular Target Erythropoietin (EPO) receptor
Mechanism of ActionErythropoietin (EPO) receptor agonist; Biosimilar
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentApproved
Standard IndicationAnemia
Indication DetailsTreat anemia in patients with chronic renal failure (CRF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today